Ciliary neurotrophic factor (CNTF) promotes skeletal muscle progenitor cell (MPC) viability via the phosphatidylinositol 3-kinase-Akt pathway

Journal of Tissue Engineering and Regenerative Medicine

Volumn 8, Issue 12, 2014, Pages 963-968

  Hiatt, Kelly ^a   Lewis, Davina ^a   Shew, Mathew ^a   Bijangi Vishehsaraei, Khadijeh ^a   Halum, Stacey ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Cell survival; Cell viability; CNTF; Muscle stem cells; Myoblasts; PI3 kinase

Indexed keywords

CYTOLOGY; MAMMALS; MUSCLE;

AKT; CELL SURVIVAL; CELL VIABILITY; CILIARY NEUROTROPHIC FACTORS; INSULIN-LIKE GROWTH FACTOR-1; MUSCLE PROGENITOR CELLS; MUSCLE STEM CELL; MYOBLASTS; PI3-KINASE; STEM-CELL;

STEM CELLS;

2 MORPHOLINO 8 PHENYLCHROMONE; CILIARY NEUROTROPHIC FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENETIC MODEL; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE STEM CELL; MYOBLAST; NONHUMAN; RAT; SKELETAL MUSCLE CELL; WILD TYPE MOUSE; ANIMAL; CYTOLOGY; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WISTAR RAT;

ANIMALS; CILIARY NEUROTROPHIC FACTOR; MALE; MUSCLE, SKELETAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84919391524     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1598     Document Type: Article

References (23)

1. Abraham MT, Gonen M, Kraus DH. 2001; Complications of type I thyroplasty and arytenoid adduction. Laryngoscope 111: 1322-1329.
2. Allen RE, Boxhorn LH. 1989; Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-β, insulin-like growth factor I, and fibroblast growth factor. J Cell Physiol 138: 311-315.
3. Bowles DW, Jimeno A. 2011; New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Drugs 20: 507-518.
4. Chen X, Mao Z, Liu S, et al. 2005; Dedifferentiation of adult human myoblasts induced by ciliary neurotrophic factor in vitro. Mol Biol Cell 16: 3140-3151.
5. Coolican SA, Samuel DS, Ewton DZ, et al. 1997; The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272: 6653-6662.
6. Goldspink GB, Wessner B, Bachl N. 2008; Growth factors, muscle function and doping. Curr Opin Pharmacol 8: 352-357.
7. Halevy O, Novitch BG, Spicer DB, et al. 1995; Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018-1021.
8. Halevy O, Cantley LC. 2004; Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs insulin-like growth factor-I in myogenic cells. Exp Cell Res 297: 224-234.
9. Halum SL, Hiatt KK, Naidu M, et al. 2008; Optimization of autologous muscle stem cell survival in the denervated hemilarynx. Laryngoscope 118: 1308-1312.
10. Halum SL, Naidu M, Delo DM, et al. 2007; Injection of autologous muscle stem cells (myoblasts) for the treatment of vocal fold paralysis: a pilot study. Laryngoscope 117: 917-922.
11. Herreros J, Prósper F, Perez A, et al. 2003; Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur Heart J 24: 2012-2020.
12. Ingram DA, Hiatt K, King AJ, et al. 2001; Hyperactivation of p21 (ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 194: 57-69.
13. Lawlor MA, Rotwein P. 2000; Coordinate control of muscle cell survival by distinct insulin-like growth factor activated signaling pathways. J Cell Biol 151: 1131-1140.
14. Liu P, Cheng H, Roberts TM, et al. 2009; Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644.
15. Maronian N. 2003; Electromyographic findings in recurrent laryngeal nerve reinnervation. Ann Otol Rhinol Laryngol 112: 314-323.
16. Mohajeri MH, Figlewicz DA, Bohn MC. 1999; Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 10: 1853-1866.
17. Pagani FD, Der Simonian H, Zawadzka A, et al. 2003; Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. J Am Coll Cardiol 41: 879-888.
18. Parker SB, Eichele G, Zhang P, et al. 1995; p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027.
19. Rodriguez R, Meuth M. 2006; Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 17: 402-412.
20. Rommel C, Bodine SC, Clarke BA, et al. 2001; Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3: 1009-1013.
21. Tucker HM. 1999; Long-term preservation of voice improvement following surgical medialization and reinnervation for unilateral vocal fold paralysis. J Voice 13: 251-256.
22. Wang X, Wu H, Zhang Z, et al. 2008; Effects of interleukin-6, leukemia inhibitory factor, and ciliary neurotrophic factor on the proliferation and differentiation of adult human myoblasts. Cell Mol Neruobiol 28: 113-124.
23. Yiou R, Yoo JJ, Atala A. 2003; Restoration of functional motor units in a rat model of sphincter injury by MPC autografts. Transplantation 76: 1053-1060.